Editor's Note
FDA Drug Trials Snapshots-A Clearer Picture
We know the risks and benefits of many drugs and devices differ in men and women. The US Food and Drug Administration (FDA) notes that both extrinsic factors (such as socioeconomic and cultural influences) and intrinsic biological factors (such as genetics, hormones, and metabolism) may vary by sex.
1 Unfortunately, women have been underrepresented in cardiovascular clinical trials for several decades, resulting in suboptimal understanding of the risks and benefits of many cardiovascular drugs and devices in women.
2
The 2012 FDA Safety and Innovation Act 3 directed the FDA to assess the inclusion, analysis, and public reporting of demographic subgroups-including by sex-in new drug, biologic, and device applications and to formulate an action plan to improve trial participation and data quality and transparency. As part of its response, the FDA has implemented Drug Trials Snapshots (DTS) for drugs approved beginning January 2015. The DTS program is a substantial step forward because the demographic characteristics of clinical trial participants are posted along with notes as to whether there were any differences in safety or efficacy by group, including sex. In this issue, Whyte and his FDA colleagues 4 review all 9 cardiovascular drugs approved during the first year of DTS, and found that women accounted for slightly more than onethird of study participants. All DTS noted similar efficacy by sex, but only 6 (67%) concluded similar safety profiles by sex. The increased transparency offered by DTS is a great step forward, and it would be even more helpful to include drugs approved prior to 2015 as well as medical devices. Drug prescribing information is available on labels, but this information is more limited than DTS and can be hard to access for patients and physicians.
How can we continue this FDA effort to improve availability of information on sex-specific risks and benefits for drugs and devices? There should be transparent tracking of demographics in premarket clinical trials of drugs and devices; such data should be examined at regular intervals to ensure that a representative patient population is being enrolled prior to application for FDA approval. New drug or device applications submitted for FDA approval with insufficient or nonrepresentative numbers of women should be returned until the drug or device sponsor has adequate safety and effectiveness data in both sexes. As documented by DTS, progress in the last 30 years has been slow, and meaningful changes will require FDA action and consequences for noncompliance; such steps are urgently needed to ensure that the benefits outweigh risks for approved drugs and devices in both women and men.
HEALTH CARE POLICY AND LAW

Military Family Physicians' Readiness for Treating Patients With Gender Dysphoria
In June 2016, the Pentagon lifted the ban on transgender personnel serving openly in the US military. As a result of the historic policy change, many military health care beneficiaries will likely seek services for gender dysphoria (GD).
Transgender individuals are overrepresented by 2:1 in the military vs in the general population, and it is estimated that nearly 13 000 transgender individuals currently serve in the US military, 200 of whom will seek GD-related treatment each year.
1 Approximately 1700 uniformed staff and resident family physicians serve in the US Army, Navy, and Air Force on active duty status. Given that family medicine physicians are responsible for the primary care of most of the active duty force and their family members seen in military treatment facilities (based on TRICARE Prime enrollment data), they will have an important role in treating service members and other beneficiaries with GD. The Department of Defense has stipulated that proficiency in transgenderrelated issues must be attained by June, 2017; however, the extent to which military clinicians currently feel competent caring for patients with GD is unknown. Most civilian practitioners receive no formal training on transgender-related services, 2,3 and patients with GD cite fear of stigma and clinicians' lack of cultural competence and sensitivity as barriers to care. 4,5 Thus, the current study assessed military physicians' readiness to treat patients with GD. electronically during or after the meeting. Of the 204 (68.0%) who participated, medical students and those who did not indicate training status (n = 24) were excluded. Sex/ gender was determined by self-report. Analyses included descriptive statistics and logistic regressions. The study was approved by the institutional review board of the Uniformed Services University of the Health Sciences.
Responding to the survey questions constituted consent to participate.
Results | Participants were primarily white (85.5%) and male (62.8%) practicing in academic medical settings (54.0%). See Table 1 for participant demographics. Since earning their licenses, 37.3% of the clinicians had cared for a patient with GD. However, a preponderance of the sample (94.9%) received 3 or fewer hours of training on transgender care during their medical education; 74.3% did not receive any training at all. Eighty-seven percent of the sample reported that they had not received sufficient education to provide cross-hormone therapy for patients ready for gender transition, and 52.9% of the sample reported that they would not personally prescribe cross-sex hormones to an adult patient, even if they were provided with additional education or the direct assistance of an experienced clinician. Most of the sample (76.1%) felt that they could provide "nonjudgmental" care to a patient with GD, and half (50.9%) agreed that exposure to openly transgender service members would increase their comfort in caring for transgender patients. Adjusting for sex, race, years of experience, and practice setting, greater medical training in transgender care was not associated with perceived ability to provide nonjudgmental 
Invited Commentary
A Transgender Military Internist's Perspective on Readiness for Treating Patients With Gender Dysphoria
Public awareness concerning transgender health care has grown over the last few years, to a degree I never expected a decade ago while attending the Uniformed Services University with Dr Klein, the senior author of a survey of the readiness of military family physicians to treat patients with gender dysphoria. 1 Unfortunately, the survey results demonstrate that physician education and comfort in treating gender dysphoria have not changed as rapidly as public awareness. The survey reveals that 74.3% of clinicians received no training at all on transgender care during their medical education. Even more disturbing, 52.9% said they would not personally prescribe cross-gender hormone treatment even if they were given additional training or guidance from an experienced clinician. I have experienced many of the shortcomings within our medical education system first-hand as a medical trainee and as a transgender patient. I first learned the term transsexual from a 1972 publication by the American Medical Association (AMA) titled Human Sexuality.
2 I found the textbook on my father's bookshelf as a 10-year-old and for the first time found a word to describe my inner world. This knowledge brought me clarity, but it did not bring me comfort. I thought at the time that I had no outlet to express my thoughts and concerns without becoming a social pariah, suitable only for sex work and entertainment. I went to medical school for a number of reasons, but primarily I wanted to heal-myself and others. As I progressed through the ranks of the medical hierarchy I gained the skills to treat a number of conditions, but gender dysphoria was not one of them. Not to say that there were not transgender soldiers in the military; however, had we been open about our condition, we would have been found unfit and discharged from the military. I continued my medical education, serving as best I could, yet the isolation, shame, and fear were constant companions. In the absence of openness, gender dysphoria could be misdiagnosed as anything from generalized anxiety disorder to bipolar disorder to addiction. Up until 2016, transgender individuals in the military were not given appropriate medical or psychological assistance. They were forced to seek help in secret, outside the military health care system, or await discharge proceedings. Although the situation has improved markedly, there is still a long way to go. We need better protocols for individuals who wish to transition while active duty, for retirees, and their family members. We need to aid them in preserving their fertility, and we need to foster an environment of openness where no soldier feels like he or she is isolated from fellow service members owing to gender identity.
With the assistance of Jesse Ehrenfeld, MD, I submitted a statement to the AMA to take a stand in support of transgender troops. In June 2015, the AMA passed a resolution affirming that there is no medically valid reason that transgender individuals cannot serve in the military.
3 Although I completed
